Certara divests medical writing arm to Veristat; software revenue rises 7%

Certara (NASDA Q:CERT) reported first-quarter 2026 revenue of $106.9 million, a 1% increase compared to the same period last year.

The marginal top-line growth masked a significant divergence in its core segments: software revenue climbed 7% to $49.7 million, while services revenue fell 4% to $57.2 million.

The company swung to a net loss of $8.8 million, or $0.06 per share, compared to net income of $4.7 million in the prior-year quarter.

On an adjusted basis, Certara posted EBITDA of $31.7 million and adjusted net income of $14.5 million.

In a strategic move to sharpen its focus on model-informed drug development, Certara finalized the sale of its global medical and regulatory writing business to Veristat.

The deal provided Certara with $85 million in immediate cash, with an additional $15 million held in escrow and a potential $35 million in performance-based earn-outs.

The Princeton, New Jersey-based firm also updated its full-year 2026 guidance to reflect the divestiture and ongoing market conditions.

Certara now expects total annual revenue between $395 million and $405 million, with an adjusted EBITDA margin target of 30% to 32%.